

2022

ANNUAL REPORT

TABLE OF CONTENTS



| | |
|----|--|
| 01 | PRESIDENT MESSAGE / 04 |
| 02 | EXECUTIVE DIRECTOR MESSAGE / 06 |
| 03 | ABOUT LACOG / 08 |
| 04 | COORDINATING OFFICE / 11 |
| 05 | LACOG MEMBERS / 12 |
| 06 | LACOG NUMBERS / 14 |
| 07 | OUR PARTNERS / 15 |
| 08 | LACOG GROUPS / 16 |
| 09 | STUDIES / 22 |
| 10 | PUBLICATIONS / 26 |
| 11 | CONFERENCES AND EVENTS / 33 |
| 12 | LOVE FOR RESEARCH AGAINST CANCER PROJECT / 40 |
| 13 | PROJETO CURA INSTITUTE / 42 |





2022: A year of expansion and consolidation



The challenge that cancer imposes on us is not only growing but also presenting itself in ever more challenging dimensions. Although it is unquestionably a global problem in terms of incidence and mortality rates, the regional context poses challenges that need a more initiative-taking and effective stance. We cannot accept as inevitable the increase in cases and fatalities. There is much work to be done to change these perspectives. The loss of life and social devastation that would result from our indifference are unacceptable.

In this context, we wish to describe this past year of LACOG as one of expansion and consolidation. We have structured a consolidated and professionalized team, which has always been the cornerstone of our strategic planning, in a consistent and organic manner. More than 40 devoted professionals engaged in the various aspects of cancer research, a new, larger, and more comfortable headquarters to accommodate our expanding needs, and an ever-increasing number of patients and studies with a growing interaction with our industry partners and international research groups attest to the undeniable fact that our organization is becoming more solid and credible.

Our national participation and influence are becoming increasingly evident. A generation of clinical-investigator physicians is being cultivated in Brazil across various specialties, stemming from a gradual process of building relationships, education, and trust that is set to continue expanding. Our regional integration is also advancing rapidly. The increasing participation of fellow researchers from the Group's sixteen member nations will coincide with LACOG's growing reputation throughout Latin American nations. The incorporation of new skills and viewpoints that will lead to further growth must go hand in hand with this integration.

Our performance could not have produced anything other than international recognition and prestige. The significant increase in the number of investigator-initiated studies, which only a few years ago was viewed as a distant utopia, is now a part of our daily existence and supports a path that will lead to ever-increasing credibility.

PRESIDENT MESSAGE 01

We are developing a culture of clinical and epidemiological research in accordance with our context, with the goal of identifying and answering questions that are significant and relevant to our population. Often groundbreaking and never-before-conducted, studies describing the reality of patients with different tumors in Latin America are supplying crucial information for the discussion and development of public policies that will improve the care of cancer patients in our region. Identifying inequities and disparities at every level is essential if we are to find the required solutions.

International clinical research is at a critical juncture and is confronted with extremely specific global challenges that are universal and directly affect us. There is a concentration of studies in certain regions or countries, and consequently, the applicability of the results to a much more heterogeneous clinical practice in the actual world is being questioned. We can and must broaden and extend the availability of studies for our region and enable the inclusion of increasingly ethnically and sociocultural diverse populations. LACOG is assisting in the development of Research Centers in institutions and regions of the country where there is no access, thereby expanding the reach and benefits of clinical research to a growing number of patients.

Only collectively, with the support of a structure such as LACOG, is it possible to realize academic and care aspirations. We are growing together and, in the process, stimulating the growth of different specialty groups that see the opportunity to learn from the experience of other colleagues and to realize academic and care goals.

Thank you very much to all who have participated in some way so far, as well as to those who are actively participating today in LACOG. We are on the move; the future is full of challenges, but we are confident that, working together, we will create a better reality for our cancer patients.

Carlos H. Barrios

02 EXECUTIVE DIRECTOR MESSAGE



A year of investigator network enhancement and **global collaboration**



Dr. Gustavo Werutsky

In 2022, LACOG expanded its network of cancer researchers from throughout Latin America. The first LACOG Annual Meeting was held in Sao Paulo, Brazil, and was a two-day event where investigators discussed study proposals, ongoing trials, publications, partnerships, and future strategies. The LACOG Annual Meeting was a milestone in the organization's history and signifies its maturity as a network of academic cancer research investigators in Latin America, thereby strengthening the culture of collaboration. Following this successful event, we held the LACOG Immuno-Oncology Symposium, which had over 1900 registrations, an average of 200 participants on-site, and 550 participants virtually, with sections on various tumor types conducted by LACOG cancer-focused groups.

An additional significant accomplishment of 2022 was the expansion of international collaboration and intergroup studies. LACOG has participated in phase III clinical trials from Breast International Group (BIG), European Organization for Research and Treatment of Cancer (EORTC), and ARCAGY-GINECO, being the continent's top recruiter in PEACE-III and in the top positions as a recruiter in the SENTICOL and IMpassion 030 studies. In addition, LACOG has joined the GOG Foundation and is preparing to participate in phase III clinical trials for gynecological cancer, which will begin in 2023. Also, another important phase III trial in prostate cancer, the DORA study, will begin in Brazil in 2023 in partnership with the Prostate Cancer Clinical Trials Consortium (PCCTC).

Recognizing the complexity of conducting and managing clinical trials and educational events, I would like to thank the entire LACOG Office team, which has been doing outstanding work to establish LACOG as an academic research group in Latin America by delivering exceptional performance and qualified work. In 2022, LACOG worked on 31 studies, completing 330 site activations, 351 regulatory submissions, 180 site contracts, 89 SIVs, and 720 monitoring visits.

Finally, I want to reiterate our mission to increase the representation and integration of Latin American investigators in LACOG. Despite the challenges and limitations, we have been increasing the number of studies and cancer-oriented group members from different Latin American countries, and we will keep working on that for the next few years.

03 ABOUT LACOG

The Latin American Cooperative Oncology Group (LACOG) is an organization dedicated to cancer research

The group is composed of physicians and researchers from various Latin American countries who collaborate to advance the knowledge and practice of oncology treatments. LACOG has 11 specialty groups in breast, gynecology, head and neck, genitourinary, lung, gastrointestinal, neuro, sarcoma, onco-geriatric, and radiotherapy.

The primary goal of LACOG is to enhance cancer treatment outcomes in the region by conducting high-quality clinical and epidemiologic research. This research seeks to evaluate new therapies and treatment methods to find the best options for the health and wellbeing of Latin American patients.

The organization also promotes continuing medical education in the field of oncology by hosting educational events and webinars and disseminating current cancer knowledge to healthcare professionals. Additionally, through its partnership with the Instituto Projeto CURA (CURE Project Institute), it supports the deliberation and formulation of cancer-related public policies in Brazil.




LACOG has been recognized as a prominent organization in the field of oncology research in Latin America, serving as a vital link between the countries of the region and international research groups.



COUNTRIES PARTICIPATING IN
LAGOG STUDIES IN LATIN AMERICA



STUDIES BETWEEN 2009 AND 2022



**04 COORDINATING
OFFICE**

The team at LACOG is comprised of highly qualified and devoted professionals who perform essential functions for the organization.

Medical Board: A medical board specializing in oncology leads LACOG and is responsible for delineating the organization's overall strategy, establishing partnerships, supervising research activities, and publishing scientific articles.

Investigators: LACOG is comprised of a team of devoted medical investigators from institutions throughout Latin America. These experts are accountable for proposing new research, conducting studies in the sites, accumulating data, and analyzing the results.

Technical/Scientific Team: LACOG also relies on statisticians, pharmacists, and biomedical specialists who assist investigators in developing research concepts and protocols, managing data monitoring, pharmacovigilance, and statistical analysis, and who contribute with knowledge and expertise to the studies and projects conducted.


Administrative Team: LACOG has an administrative team that manages the daily operations of the organization. This includes financial management, human resources, communication, and information technology, which guarantee the group's efficient operation.



05 LACOG MEMBERS


Investigators play a key role in LACOG and are essential to the organization's success. Today, the group has **507 members** who play a vital role in producing scientific evidence, advancing knowledge, and enhancing cancer treatment in Latin America.

The collaboration of everyone involved contributes to the creation of novel clinical and epidemiological studies and has direct effects on the clinical practice and care of cancer patients in the region.




Medical Speciality

- Oncologist 81.2%
- Surgeon 7.2%
- Other Medical Specialty 6.4%
- Radiation Oncologist 4.5%
- Pathologist 0.7%




Types of tumor studies members are interested in

- Breast 20.3%
- Genitourinary 14.6%
- Gynecological 13.8%
- Gastrointestinal 13.3%
- Lung 10.2%
- Geriatric Oncology 5.5%
- Head and Neck 5.2%
- Melanoma 4.7%
- Sarcoma 4.4%
- Soft tissue sarcoma 3.6%
- Central Nervous System 2.9%
- Radiation Oncology 1.0%
- Hematology 0.5%



Institution Experience

- Clinical Trials and Epidemiological 74.8%
- Clinical Trials 12.9%
- Epidemiological 7.5%
- None of the above 4.8%



Experience as a Principal Investigator

- Yes 86.8%
- No 13.2%

06 LACOG NUMBERS



507
MEMBERS



265
HOSPITALS AND
RESEARCH SITES



16
COUNTRIES

Argentina, Brazil, Bolivia, Colombia, Chile, Costa Rica, Cuba, El Salvador, Ecuador, Guatemala, Mexico, Nicaragua, Panama, Peru, Uruguay and Venezuela



70
EPIDEMIOLOGICAL STUDIES
AND CLINICAL TRIALS



12.500
PATIENTES ENROLLED



115
ABSTRACTS AND
ARTICLES PUBLISHED



28
EDUCATIONAL EVENTS
PERFORMED

07 OUR PARTNERS

LACOG collaborates with national and international study groups, participating in the development and management of epidemiological studies and clinical trials.



LACOG IS MEMBER OF



08

LACOG GROUPS



BOARD MEMBERS GENITOURINARY GROUP



LACOG GENITOURINARY
GROUP CHAIR

**Dr. Diogo
Rodrigues Rosa**

Oncoclínicas Group
Rio de Janeiro, RJ, Brazil



SCIENTIFIC DIRECTOR

**Dr. Denis
Jardim**

Sírio Libanês Hospital
São Paulo, SP, Brazil



EXECUTIVE DIRECTOR

**Dr. Diogo
Assed Bastos**

Oncoclínicas Group
Rio de Janeiro, RJ, Brazil



EDUCATIONAL DIRECTOR

**Dr. Karine
Trindade**

Oncocentro
São Carlos Hospital
Fortaleza, CE, Brazil



SECRETARY

Dr. Fábio Kater

The Beneficência
Portuguesa of São Paulo
São Paulo, SP, Brazil



BOARD MEMBERS GYNECOLOGICAL GROUP



LACOG GYNECOLOGICAL
GROUP CHAIR

**Dr. Angélica
Nogueira**

UFMG - Federal University of
Minas Gerais
Belo Horizonte, MG, Brazil



VICE-CHAIR

Dr. Graziela Dal Molin

The Beneficência
Portuguesa of São Paulo
São Paulo, SP, Brazil



SECRETARY

Dr. Fernanda Damian

São Lucas da PUCRS Hospital
Porto Alegre, RS, Brazil



BOARD MEMBERS **BREAST** GROUP



LACOG BREAST
GROUP CHAIR
Dr. Gustavo Werutsky
São Lucas da PUCRS
and Moinhos de Vento
Hospital
Porto Alegre, RS, Brazil



VICE-CHAIR
Dr. Max Senna Mano
Oncoclínicas Group São Paulo
São Paulo, SP, Brazil



SECRETARY
Dr. Paula Cabrera
INCAN - National Institute
of Cancerology
Ciudad de Mexico, Mexico



SCIENTIFIC DIRECTOR
Dr. José Bines
INCA - National Institute
of Cancer
Rio de Janeiro, RJ, Brazil



BOARD MEMBERS **LUNG** GROUP



LACOG LUNG
GROUP CHAIR
Dr. Gilberto Castro
ICESP - The Cancer Institute
of the State of São Paulo
São Paulo, SP, Brazil



VICE-CHAIR
Dr. Ana Gelatti
São Lucas da PUCRS Hospital
Porto Alegre, RS, Brazil



SECRETARY
Dr. Clarissa Baldotto
D'Or Oncology
Rio de Janeiro, RJ, Brazil



BOARD MEMBERS **HEAD AND NECK** GROUP



LACOG HEAD AND
NECK GROUP CHAIR
Dr. Aline Lauda F. Chaves
DOM Oncology
Divinópolis, MG, Brazil



CO-CHAIR
Dr. William Nassib Jr.
Oncoclínicas Group
São Paulo, SP, Brazil



EXECUTIVE DIRECTOR
Dr. Luiz Paulo Kowalski
A.C Camargo Cancer Center
São Paulo, SP - Brazil



SECRETARY
Dr. Gilberto Castro
ICESP - The Cancer Institute of
the State of São Paulo
São Paulo, SP, Brazil



BOARD MEMBERS **RADIATION** GROUP



LACOG RADIATION
GROUP CHAIR
Dr. Maurício Fraga da Silva
The University Hospital of
Santa Maria
Santa Maria, RS, Brazil



VICE-CHAIR
Dr. Gustavo Nader Marta
ICESP
Sírio-Libanês Hospital
São Paulo, SP, Brazil



SECRETARY
Dr. Fábio Moraes
Radiation Medicine Program -
Princess Margaret Cancer Centre
Toronto, Canada



BOARD MEMBERS **NEURO** GROUP



LACOG NEURO
GROUP CHAIR
**Dr. Camilla
Akemi Felizardo
Yamada**
The Beneficência
Portuguesa of São Paulo
São Paulo, SP, Brazil



VICE-CHAIR
Dr. Fernando Maluf
The Beneficência Portuguesa of São Paulo
São Paulo, SP, Brazil



SECRETARY
**Dr. Suzana Maria
Fleury Malheiros**
Israelita Albert Einstein Hospital
São Paulo, SP, Brazil



BOARD MEMBERS **GERIATRIC ONCOLOGY** GROUP



LACOG GERIATRIC
ONCOLOGY GROUP CHAIR
**Dr. Luciola
Pontes**
Hcor
São Paulo, SP, Brazil



VICE-CHAIR
Dr. Ludmila Muniz Koch
Israelita Albert Einstein Hospital
São Paulo, SP, Brazil



SECRETARY
Dr. Jurema Telles
IMIP - Institute of Integral Medicine
Professor Fernando Figueira
Recife, PE, Brazil



BOARD MEMBERS **GASTROINTESTINAL** GROUP



LACOG
GASTROINTESTINAL
GROUP CHAIR
**Dr. Rachel
Riechelmann**
A.C Camargo Cancer Center
São Paulo, SP, Brazil



VICE-CHAIR
Dr. Anelisa Coutinho
AMO Clinic – Multidisciplinary
Support in Oncology
Salvador, BA, Brazil



SECRETARY
Dr. Renata D'alpino Peixoto
Alemão Oswaldo Cruz Hospital
São Paulo, SP, Brazil



BOARD MEMBERS **SARCOMA** GROUP



LACOG SARCOMA
GROUP CHAIR
**Dr. Roberto
Pestana**
Israelita Albert
Einstein Hospital
São Paulo, SP, Brazil



VICE-CHAIR
**Dr. Reynaldo Jesus
Garcia Filho**
Israelita Albert Einstein Hospital
São Paulo, SP, Brazil



SECRETARY
**Dr. Rafael
Schmerling**
HCOR Hospital
São Paulo, SP, Brazil

09 LACOG STUDIES

LUNG

| STUDY NAME | TYPE OF STUDY | SPONSOR / SUPPORT | TITLE | SAMPLE SIZE | COUNTRIES LATAM |
|----------------------------|-----------------|----------------------------|--|--------------|---|
| LACOG 0116 LATINO LUNG | Epidemiological | LACOG / BMS / Pfizer | Prospective epidemiological study of metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America | 728 patients | Argentina, Brazil, Colombia, Mexico and Uruguay |
| LACOG 0118 RELANCE | Epidemiological | LACOG / GBOT / AstraZeneca | Retrospective epidemiological study of Locally Advanced Non Small Cell Lung Cancer | 403 patients | Brazil |
| LACOG 0417 CNS MTX | Epidemiological | LACOG / GBOT | Retrospective Analysis of Patients with Non-Small Cell Lung Cancer with Brain Metastasis | 385 patients | Brazil |
| LACOG 1918 Patient Journey | Epidemiological | LACOG / GBOT / Takeda | Patient Journey with advanced lung cancer positive for ALK fusion in Brazil | 100 patients | Brazil |
| LACOG 2218 PACIFIC BRAZIL | Clinical Trial | LACOG / AstraZeneca | Intensified chemo-immuno-radiotherapy with durvalumab (MEDI4736) for stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II study (PACIFIC BRAZIL) | 48 patients | Brazil |
| LACOG 0120 EAP Durva | Epidemiological | LACOG / GBOT | Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real World Data from an Expanded Access Program in Brazil | 36 patients | Brazil |
| LACOG 0322 EDUR BRA | Epidemiological | LACOG / GBOT / Astrazeneca | A Real-World Assessment of the Efficacy and Safety of Durvalumab Associated with Platinum-Etoposide in Previously Untreated Extensive Stage-Small Cell Lung Cancer (ES-SCLC) in Brazil | 60 patients | Brazil |
| LACOG 0821 AMIGO-1 | Clinical Trial | LACOG / Janssen | A single arm, phase 2 study of amivantamab, lazertinib and pemetrexed for first-line treatment of recurrent / metastatic non-small cell lung cancers (NSCLCs) with EGFR mutations | 49 patients | Brazil |

BREAST

| STUDY NAME | TYPE OF STUDY | SPONSOR / SUPPORT | TITLE | SAMPLE SIZE | COUNTRIES LATAM |
|-------------------------------------|-----------------|-----------------------|---|----------------|---|
| LACOG 0615 LATINA Breast | Epidemiological | LACOG/ Roche | A study to observe patients characteristics, treatment patterns and outcomes in patients with newly diagnosed breast cancer in Latin America. | 4.500 patients | Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Cuba, Ecuador, Guatemala, Mexico, Peru, Republica Dominicana Uruguay and Venezuela |
| LACOG 0413 Male Breast Cancer | Epidemiological | EORTC | Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study. | 533 patients | Brazil, Mexico and Peru |
| GBECAM 0115 - AMAZONA III | Epidemiological | LACOG GBECAM / PRONON | Prospective evaluation of breast cancer at Brazilian institutions - Project AMAZONA III | 3.000 patients | Brazil |
| LACOG 0715 - PALLAS | Clinical Trial | ABCSG ALLIANCE | A randomized phase III trialof palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast Cancer | 4.600 patients | Mexico |
| LACOG 2118 ALEXANDRA/ IMpassion 030 | Clinical Trial | ABCSG BIG AFT | A phase III, multicenter, randomized, open-label study comparing Atezolizumab (ANTI-PD-L1 ANTIBODY) in combination with adjuvant Anthracycline/Taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer. | 2.300 patients | Brazil and Mexico |
| GBECAM/ LACOG 0419 - NEOSAMBA | Clinical Trial | LACOG GBECAM | Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer | 444 patients | Brazil |
| LACOG 0221 - BRAVE | Epidemiological | LACOG GBECAM | Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil (LACOG 0221) – BRAVE Study | 300 patients | Brazil |

HEAD AND NECK

| STUDY NAME | TYPE OF STUDY | SPONSOR / SUPPORT | TITLE | SAMPLE SIZE | COUNTRIES LATAM |
|----------------------|-----------------|-------------------|--|--------------|-----------------|
| LACOG 0319 | Epidemiological | LACOG | Quality Of Life Assessment Study In Patients With Metastatic Head And Neck Neoplasia Submitted To Immunotherapy In Brazil | 100 patients | Brazil |
| LACOG 0720 SMART-KEY | Clinical Trial | LACOG / MSD | SMART-KEY: A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers | 41 patients | Brazil |

NEURO

| STUDY NAME | TYPE OF STUDY | SPONSOR / SUPPORT | TITLE | SAMPLE SIZE | COUNTRIES LATAM |
|----------------------------|-----------------|-------------------|---|--------------|-----------------|
| LACOG 0619 Glioma Registry | Epidemiological | LACOG | Characterization of patients with diffuse gliomas in Brazil | 300 patients | Brazil |

GENITOURINARY

| STUDY NAME | TYPE OF STUDY | SPONSOR / SUPPORT | TITLE | SAMPLE SIZE | COUNTRIES LATAM |
|-------------------------------------|-----------------|-------------------|---|-----------------------------|-----------------|
| LACOG 0217 IRONMAN | Epidemiological | PCCTC | IRONMAN: International Registry for Men with Advanced Prostate Cancer | 5.000 patients (100 Brazil) | Brazil |
| LACOG 1818 Prostate Cancer Registry | Epidemiological | LACOG/ LACOG GU | Survival outcomes in metastatic prostate cancer in the Brazilian population - analysis of individual characteristics and treatment modalities in different national health institutions | 590 patients | Brazil |
| LACOG 0218 Hercules | Clinical Trial | LACOG/ MSD | A phase II trial of pembrolizumab combined with cisplatin-based chemotherapy as first-line systemic therapy in advanced penile cancer | 37 patients | Brazil |
| LACOG 0519 PEACE III | Clinical Trial | EORTC | A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III | 560 patients (106 Brazil) | Brazil |
| LACOG 0620 - ExBAT | Clinical Trial | LACOG/BAYER | Extreme Bipolar Androgen Therapy with Darolutamide and Testosterone Cypionate in Patients with Metastatic Castration-Resistant Prostate Cancer (ExBAT trial) | 51 patients | Brazil |
| LACOG 2018 | Epidemiological | LACOG | Molecular Characterization of Penile Cancers in Developing Countries | 20 patients | Brazil |
| LACOG 0121 - PET - PMSA | Epidemiological | LACOG Astellas | Retrospective analysis of 68Ga-PSMA-PET in patients with prostate cancer: experience from Brazil | 300 patients | Brazil |
| LACOG 1120 - RENAL REGISTRY | Epidemiological | LACOG/ Ypsen | Clinicopathological characteristics and outcomes of patients with Renal Cell Carcinoma in Latin America | 204 patients | Brazil |

GASTROINTESTINAL

| STUDY NAME | TYPE OF STUDY | SPONSOR / SUPPORT | TITLE | SAMPLE SIZE | COUNTRIES LATAM |
|----------------------|-----------------|----------------------|---|--------------|--|
| LACOG/GTG 1318 - CCA | Epidemiological | LACOG, GTG | A multicenter retrospective database on prognostic and predictive factors in patients with squamous cell carcinoma of the anus. | 300 patients | Brazil |
| LACOG 0119 NET | Epidemiological | LACOG, GTG | A multicenter retrospective database on prognostic and predictive factors in patients with neuroendocrine tumors | 300 patients | Brazil, Mexico, Peru, Chile, Argentina |
| LACOG 0222 GASPARG | Epidemiological | LACOG, GTG, Astellas | Epidemiological characteristics of gastric and pancreatic cancers in Latin America (LACOG 0222) | 200 patients | Brazil, Argentina, Mexico, Dominican Republic, Chile, Colombia |
| LACOG/GTG 0421 | Epidemiological | LACOG, GTG | A global record of patients with anal squamous cell carcinoma with and without HIV infection | 300 patients | Brazil, Peru, Mexico, Argentina, Chile, UK |

GYNECOLOGICAL

| STUDY NAME | TYPE OF STUDY | SPONSOR / SUPPORT | TITLE | SAMPLE SIZE | COUNTRIES LATAM |
|------------------------------------|-----------------|---|---|---------------------------|--|
| LACOG 0215 EVITA | Epidemiological | LACOG, Roche | Prospective evaluation of patients with uterine cervical cancer in Brazilian health institutions | 800 patients | Brazil |
| LACOG 1018 PALBO in Ovarian Cancer | Clinical Trial | LACOG/Pfizer | Palbociclib plus letrozole combination after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer | 39 patients | Brazil |
| LACOG 0920 Senticol III | Clinical Trial | Centre Hospitalier Universitaire de Besançon/ LACOG | International Validation Study Of Sentinel Node Biopsy In Early Cervical Cancer | 988 patients (200 Brazil) | Brazil, China, Italia, França, Canada e Japão |
| LACOG 0820 EVITA LATAM | Epidemiological | LACOG/AZ | EVITA LATAM: Epidemiological Landscape of Cervical Cancer in Latin America | 482 patients | Brazil, Mexico, Colombia, Peru, Argentina, Guatemala, Dominican Republic |

RADIATION

| STUDY NAME | TYPE OF STUDY | SPONSOR / SUPPORT | TITLE | SAMPLE SIZE | COUNTRIES LATAM |
|--------------------|-----------------|-------------------|--|--------------|-----------------|
| LACOG 0122 RADIANT | Epidemiological | LACOG | Radiotherapy with extreme hypofractionation in patients with breast cancer in Brazil: a retrospective cohort study | 363 patients | Brazil |

10 PUBLICATIONS

ABSTRACTS

Journal of Clinical Oncology 40, no. 16

Clinicopathological characterization, FGFR alteration prevalence, and outcomes of locally advanced or metastatic urothelial cancer in Latin America (LACOG 1518).

Vinicius Carrera Souza, Andrey Soares, Fernando Cotait Maluf, Fernando Sabino Marques Monteiro, Rosemarie Gidekel, Jaime Ardila-Salcedo, Maria Natalia Gandur-Quiroga, Murilo Luz, Marcelo Roberto Pereira Freitas, Saul Campos-Gomez, José Augusto Rinck, Juan Pablo Sade, Diogo Assed Bastos, Karine Trindade, Augusto C. A. Mota, Allan Barillas, Roni de Carvalho Fernandes, Rafaela Gomes, Gustavo Cartaxo de Lima Gössling, Andre P. Fay

EP03.01 EPIDEMIOLOGY| VOLUME 17, ISSUE 9, SUPPLEMENT , S237-S238, SEPTEMBER 2022

EP03.01-003 Clinical Features and Molecular Profile of Advanced Non-small Cell Lung Cancer in Latin America: LATINO Lung (LACOG 0116)

G. Werutsky, O. Arrieta, M. Zukin, C. Mathias, A.C.Z. Gelatti, D.L. Kaen, A.F. Cardona, E. Cronenberg, C. Campos, L.H. Araújo, H. de Andrade, S.L. Reichow, V.C. de Lima, P. Pacheco, J.C. Coelho, G. Borges, A. Silva, E. Mascarenhas, A. Quiroga, L. Fein, F.N.G. de Oliveira, J. Pastorello, C. Dutra, I. Morbeck, F.S.M. Cruz, T.F. Rebelatto, R. Gomes, C.H. Barrios

VOLUME 33, SUPPLEMENT 7, S733, SEPTEMBER 2022

435P Cisplatin versus mitomycin plus fluoropyrimidine and radiation for localized squamous cell carcinoma of the anus (SCCA): Final results of GTG-LACOG 1318 real-world data study

R.S.P. Riechelmann, A. Kruschewsky Coutinho Araujo, G. dos Santos Fernandes, R. Weschenfelder, D.R.D. Rocha Filho, L.A. Schlittler, J.F.D.M. Rego, G. Prola, R.G. de Jesus, G.C.D.L. Gössling, R. D'Alpino Peixoto

International Journal of Gynecologic Cancer 2022;32:A243.

TP040/#1418 Palbociclib plus letrozole combination after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer (LACOG 1018)

Fernanda Damian, Graziela Zibetti Dal Molin, Angelica Rodrigues, Aknar De Carvalho Calabrich, Gustavo Werutsky, Elias Abdo Filho, Mirela Foresti Jimenez, Taiane Rebelatto, Rafaela De Jesus and Andreia Cristina De Melo

International Journal of Gynecologic Cancer 2022;32:A227.

TP008/#1422 Epidemiological landscape of cervical cancer in Latin America (EVITA LATAM) – LACOG 0820

Graziela Zibetti Dal Molin, Mivael Olivera, Adrian Guerrero, Reitan Ribeiro, Juan Zarba, Andreia Cristina De Melo, Gustavo Werutsky, Heloisa De Andrade Carvalho, Juan Velasquez, Alexssandra Siqueira Dos Santos, Fernanda Damian, Eduardo Cronenberg, André Mattar, Lucely Cetina-Perez, Miriam Raimondo, Natalia Baltz Hehn, Ronaldo Schmidt, Vanessa Bezerra, Rafaela De Jesus, Taiane Rebelatto and Renata Colombo Bonadio

Journal of Clinical Oncology - Volume 40, Issue 16_suppl >

Survival analysis of the randomized phase II trial to investigate androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.

Fernando Cotait Maluf, Andrey Soares, Diogo Assed Bastos, Fabio A. B. Schutz, Eduardo Cronemberger, Murilo Luz, Suelen P. S. Martins, David Queiroz Borges Muniz, Flavio Mavignier Carcano, Oren Smaletz, Fábio A Peixoto, Andrea J Gomes, Felipe Melo Cruz, Fabio Franke, Daniel Herchenhorn, Rosemarie Gidekel, Taiane Francieli Rebelatto, Rafaela Gomes, Vinicius Carrera Souza, Andre P. Fay

ARTICLES

ORIGINAL STUDY| VOLUME 21, ISSUE 3, E104-E113, JUNE 2023

Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515)

Diogo A. Bastos, Aline Bobato Lara Gongora, Carlos Dzik, Fabio A. Schutz, Oren Smaletz, Andre P. Fay

BJOncology

Subgroup analysis of Brazilian participants of a medical leadership competencies instrument: a cross-sectional survey study of the Latin American Cooperative Oncology Group (LACOG) and the Academy of Leadership Sciences Switzerland (ALSS)

Max Senna Mano; Rafaela Gomes Jesus; Carlos Henrique Escosteguy Barrios; Wanessa Cassemiro Fernandes; Leandro Jonata de Carvalho Oliveira; Abna Faustina Sousa Vieira; Renan Orsati Clara; Antônio Luiz Frasson; Gustavo Nader Marta; Sérgio Daniel Simon; Cynthia Villarreal-Garza; Gustavo Werutsky; Fadil Çitaku

Breast Cancer Research and Treatment volume 198, pages123–130

Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)

Raira Mesquita Maschmann, Rafaela Gomes De Jesus, Gustavo Werutsky, Taiane Francieli Rebelatto, Geraldo Queiroz, Sergio Daniel Simon, José Bines, Carlos Henrique Escosteguy Barrios & Daniela Dornelles Rosa

The Lancet Regional Health - Americas | Volume 11, July 2022, 100254

Barriers and facilitators to provide multidisciplinary care for breast cancer patients in five Latin American countries: A descriptive-interpretative qualitative study

Carlos Barrios a, Guillermo Sánchez-Vanegas b f, Cynthia Villarreal-Garza c, Andrés Ossa d, Milton A. Lombana e, Angélica Monterrosa-Blanco b, Ana S. Ferrigno c, Carlos Alberto Castro b f

The Lancet Oncology, Volume 23Number 1p1-184, e1-e44

European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer

Icro Meattini, Carlotta Becherini, Liesbeth Boersma, Orit Kaidar-Person, Gustavo Nader Marta, Angel Montero, Birgitte Vrou Offeren, Marianne C Aznar, Claus Belka, Adrian Murray Brunt, Samantha Dicuonzo, Pierfrancesco Franco, Mechthild Krause, Mairead MacKenzie, Tanja Marinko, Livia Marrazzo, Ivica Ratos, Astrid Scholten, Elzbieta Senkus, Hilary Stobart, Philip Poortmans, Charlotte E Coles

Archives of Medical Research | Volume 53, Issue 8, December 2022, Pages 818

Socioeconomic Impact of Cancer in Latin America and The Caribbean

Gustavo Werutsky a, Gustavo Gössling a, Rodrigo Azevedo Pellegrini b, Gustavo Alberto Sandival Ampuero c, Taiane Rebelatto a

Supportive Care in Cancer volume 30, pages4399–4406 (2022)

Influence of physician's lifestyle on the prescription of healthy habits to breast cancer patients (LACOG 1218)

Renata Cangussú, Eldsamira Mascarenhas, Taiane Francieli Rebelatto, Facundo Zaffaroni, Rafaela Gomes de Jesus, Paulo Ricardo Nunes Filho, Gustavo Werutsky

JCO Global Oncology no. 8 (2022) e2100333. Published online April 25, 2022.

Non-Small-Cell Lung Cancer With CNS Metastasis: Disparities From a Real-World Analysis (GBOT-LACOG 0417)

Juliano Cé Coelho, Giselle de Souza Carvalho, Fabio Chaves, Pedro de Marchi, Gilberto de Castro Jr, Clarissa Baldotto, Eldsamira Mascarenhas, Patricia Pacheco, Rafaela Gomes, Gustavo Werutsky and Luiz H. Araujo.

ARTICLES

LACOG AFFILIATION

Radiother Oncol. 2022 Jun;171:7-13

Moderate hypofractionation for salvage radiotherapy (HYPO-SRT) in patients with biochemical recurrence after prostatectomy: A cohort study with meta-analysis
Gustavo Arruda Viani, Andre Guimaraes Gouveia, Elton Trigo Teixeira Leite, Fabio Ynoe Moraes

Reports of Practical Oncology and RadiotherapyVol 27, No 4 (2022)

Impact of COVID-19 on the curative treatment of prostate cancer: a national cross-sectional study
Andre G Gouveia, Fabio Y Moraes, Renato P Lima, Gustavo A Viani

Journal of Cancer Policy | Volume 36, June 2023, 100367

Radiotherapy activity in the COVID 19 pandemic: Brazil's operational national-level study
Fabio Y Moraes, Andre G Gouveia, Renato P Lima, Vanessa F Bratti, Ana C Hamamura, Gustavo A Viani

Radiother Oncol. 2022 Dec;177:245-246

In reply to Li et al. Letter to the editor. "Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials."
Gustavo A. Viani, Andre G. Gouveia, Fabio Y. Moraes

The Lancet Regional Health - Americas | Volume 11, July 2022, 100254

Barriers and facilitators to provide multidisciplinary care for breast cancer patients in five Latin American countries: A descriptive-interpretative qualitative study
Carlos Barrios, Guillermo Sánchez-Vanegas, Cynthia Villarreal-Garza, Andrés Ossa, Milton A Lombana, Angélica Monterrosa-Blanco, Ana S Ferrigno, Carlos Alberto Castro

The Lancet Regional Health - Americas | Volume 14, October 2022, 100323

Moderately hypofractionated radiation therapy for breast cancer: A Brazilian cohort study
Gabriela S M de Siqueira , Samir A Hanna , Larissa F de Moura , Fabiana Accioli Miranda , Heloísa de Andrade Carvalho, Gustavo Nader Marta

The Lancet Regional Health - Americas | Volume 13, September 2022, 100292

Cost containment analysis and access to treatment associated with adopting hypofractionated radiation therapy from the Brazilian perspective
Prince Taylor , Marcus Simões Castilho , Gustavo Nader Marta

Onco Targets Ther J. 2022 Dec 21;15:1531-1542

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
Mariane S Fontes, Daniel Vargas Pivato de Almeida, Clarissa Cavalin, Scott T Tagawa

ARTICLES

LACOG AFFILIATION

Front. Endocrinol., 24 November 2022, Sec. Cancer Endocrinology | Volume 13 - 2022

Clinical implication of low estrogen receptor (ER-low) expression in breast cancer
Tomás Reinert, Fanny Cascelli, Cristiano Augusto Andrade de Resende, Aline Coelho Gonçalves, Vania Sanchez Prette Godo, Carlos Henrique Barrios

Scientific Reports volume 12, Article number: 20645 (2022)

Oral Lichen Planus and Oral Squamous Cell Carcinoma share key oncogenic signatures
Cristóvão Antunes de Lanna, Beatriz Nascimento Monteiro da Silva, Andreia Cristina de Melo, Martín H Bonamino, Lísia Daltro Borges Alves, Luis Felipe Ribeiro Pinto, Abel Silveira Cardoso, Héilton Spindola Antunes, Mariana Boroni, Daniel Cohen Goldemberg

Nature Reviews Clinical Oncology volume 20, pages7–15

Barriers in access to oncology drugs - a global crisis
Carlos Barrios, Gilberto de Lima Lopes, Mastura Md Yusof, Fidel Rubagumya, Piotr Rutkowski, Manju Sengar

JCO Global Oncology no. 8 (2022) e2200289. Published online November 9, 2022.

Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil
Cristiano A A Resende, Heloísa M Fernandes Cruz, Matheus Costa E Silva, Rafael D Paes, Rodrigo Dienstmann, Carlos H E Barrios, Aline C Goncalves, Fanny G A Cascelli, Andreza K B A Souto, Leandro C Oliveira, Tomás Reinert, Diocesio A P Andrade, Mauro P Passos , Eduardo C Millen, Felipe Zerwes, Paulo L Moraes, Bruno L Ferrari, Max S Mano

Gynecologic Oncology, VOLUME 167, ISSUE 3, P540-546

Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer
Maria Rubinstein, Sherry Shen, Bradley J Monk, David S P Tan, Angélica Nogueira-Rodrigues, Daisuke Aoki, Jalid Sehouli, Vicky Makker

Clinical Genitourinary Cancer, VOLUME 21, ISSUE 2, E58-E69

Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil
Denis L Jardim, Adriano Gonçalves E Silva, Alexandre Saad Fere Lima Pompeo, Alvaro Sadek Sarkis, Ana Paula Garcia Cardoso, Andre Deeke Sasse, Andre Poisl Fay, Andrey Soares, Antonio Carlos Lima Pompeo, Arie Carneiro, Ariel Galapo Kann, Camilla Fogassa, Celso Heitor De Freitas Junior, Daher Cezar Chade, Daniel Herchenhorn, Daniel Vargas Pivato De Almeida, Diogo Augusto Rodrigues Da Rosa, Evanius Garcia Wiermann, Fabio Augusto Barros Schutz, Fabio Roberto Kater, Fernando De Moura, Fernando Korkes, Fernando Meyer, Fernando Nunes Galvao De Oliveira, Fernando Sabino, Gilberto Laurino Almeida, Guilherme Avanço, Gustavo Cardoso Guimaraes, Gustavo Caserta Lemos, Gustavo Franco Carvalhal, Hanna Kim, Igor Protzner Morbeck, Joao Carlos Campagnari, Jose Augusto Rinck Junior, José Ricardo Tuma Da Ponte, Karine Martins Da Trindade, Leonardo Atem, Leonardo Borges, Lucas Mendes Nogueira, Lucas Teixeira E Aguiar Batista, Manuel Caitano Maia, Marcus Vinicius Sadi, Maria Alzira Almeida Rocha, Murilo De Almeida Luz, Oren Smaletz, Paulo Sergio Moraes Lages, Raquel Midori Koga Matuda, Rodolfo Borges Dos Reis, Rodrigo Frota Indio, Roni De Carvalho Fernandes, Sandro Roberto Cavallero, Vinicius Carrera Souza, Wilson Busato Jr, Wladimir Alfer Junior, Fernando Maluf

Reports of Practical Oncology and RadiotherapyVol 27, No 3

Triple-negative breast cancer and radiation therapy
Jordana de Faria Bessa, Gustavo Nader Marta

ARTICLES

LACOG AFFILIATION

ESMO Open

Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer

R Wuerstlein, P Ellis 2, F Montemurro, A Antón Torres, S Delaloge, Q Zhang, X Wang, S Wang, Z Shao, H Li, A Rachman, M Vongsaisuwon, H Liu, S Fear, C Peña-Murillo, C Barrios

Cancers (Basel)

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study

Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Giacomo Nuvola, Matteo Rosellini, Elisa Tassinari, Javier Molina-Cerrillo, Zin W Myint, Tomas Buchler, Fernando Sabino Marques Monteiro, Enrique Grande, Matteo Santoni, Francesco Massari

Cancer Treatment Reviews - VOLUME 110, 102459

Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?

Renata Colombo Bonadio, Paolo Tarantino, Laura Testa, Kevin Punie, Sonia Pernas, Carlos Barrios, Giuseppe Curigliano, Sara M Tolaney, Romualdo Barroso-Sousa

Nature Medicine volume 28, pages1738–1739

Choosing Wisely for oncology in Brazil: 10 recommendations to deliver evidence-based cancer care

Fabio Ynoe de Moraes, Gustavo Nader Marta , Gunita Mitera, Daniel Neves Forte, Rodrigo Nascimento Pinheiro, Nivaldo F Vieira, Rafael Gadia, Maira Caleffi, Patricia Chiappin Kauer, Luciana Holtz de Camargo Barros, Clarissa Mathias, Karina Gondim Moutinho da Conceicao Vasconcelos, Christopher Booth, Gustavo Dos Santos Fernandes

European Journal of Cancer, volume 173

Implications of the PEARL trial from the low- to middle-income countries' perspectives

Tomás Reinert, Aline C Gonçalves, C A A de Resende, Carlos H Barrios

Gynecologic Oncology Reports | Volume 42

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer

Jeffrey C H Goh, Charlie Gourley, David S P Tan, Angélica Nogueira-Rodrigues, Hesham Elghazaly, Marc Edy Pierre, Gonzalo Giornelli, Byoung-Gie Kim, Flavia Morales-Vasquez, Alexandra Tyulyandina

Critical Reviews in Oncology/Hematology | Volume 176

Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival

Matteo Santoni, Fernando Sabino M Monteiro, Francesco Massari, Halima Abahssain, Gaetano Aurilio, Javier Molina-Cerrillo, Zin W Myint, Ignacio Ortego Zabalza, Nicola Battelli, Enrique Grande

BMC Urology volume 22, Article number: 86

Knowledge, attitudes, and practices of active surveillance in prostate cancer among urologists: a real-life survey from Brazil

Marcelo Langer Wroclawski, Breno Santos Amaral, Paulo Priante Kayano, Wilson Francisco Schreiner Busato Jr, Sebastião José Westphal, Erik Montagna, Bianca Bianco, Andrey Soares, Fernando Cotait Maluf, Gustavo Caserta Lemos, Arie Carneiro

ARTICLES

LACOG AFFILIATION

American Society of Clinical Oncology Educational Book > List of Issues > Volume 42

Drug Development in Low- and Middle-Income Countries: Opportunity or Exploitation?

Rakesh Jalali 1, Angelica Nogueira-Rodrigues 2, Arunangshu Das 3, Bhawna Sirohi 4, Pankaj Kumar Panda 5

Clinical Genitourinary Prostate, Kidney, & Bladder Cancer, VOLUME 20, ISSUE 5, P391-398

A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)

Fernando Sabino M Monteiro, Andrey Soares, Vinicius Carrera Souza, Rubens Copia Sperandio, Enrique Grande, Matteo Santoni, Andre Poisl Fay, Andre Deeke Sasse

European Journal of Cancer, volume 166

Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients

Marion T van Mackelenbergh, Fenja Seither, Volker Möbus, Joyce O'Shaughnessy, Miguel Martin, Heikki Joensuu, Michael Untch, Ulrike Nitz, Guenther G Steger, Juan J Miralles, Carlos H Barrios, Masakazu Toi, Harry D Bear, Hyman Muss, Toralf Reimer, Valentina Nekljudova, Sibylle Loibl

The Breast, Volume 62, Supplement 1, S3-S-6

Global challenges in breast cancer detection and treatment

Carlos H Barrios

Journal of Thoracic Oncology, | VOLUME 17, ISSUE 5, P651-660

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials

Matthew P Smeltzer, Giorgio V Scagliotti, Heather A Wakelee, Tetsuya Mitsudomi, Upal Basu Roy, Russell C Clark, Renee Arndt, Clayton D Pruett, Karen L Kelly, Peter Ujhazy, Melissa L Johnson , Yesim Eralp, Carlos H Barrios, Fabrice Barlesi, Fred R Hirsch, Paul A Bunn;

The Breast, VOLUME 62, P84-92

Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials

Gustavo Nader Marta, Rachel Riera, Rafael Leite Pacheco, Ana Luiza Cabrera Martimbianco, Icro Meattini, Orit Kaidar-Person, Philip Poortmans

The Lancet Oncology, VOLUME 23, ISSUE 1, E21-E31

European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer

Icro Meattini, Carlotta Becherini, Liesbeth Boersma, Orit Kaidar-Person, Gustavo Nader Marta, Angel Montero, Birgitte Vrou Offersen, Marianne C Aznar, Claus Belka, Adrian Murray Brunt, Samantha Dicuonzo, Pierfrancesco Franco, Mechthild Krause, Mairead MacKenzie, Tanja Marinko, Livia Marrazzo, Ivica Ratoso, Astrid Scholten, Elżbieta Senkus, Hilary Stobart, Philip Poortmans, Charlotte E Coles

International Journal of Gynecological Cancer, Volume 32, Issue 2

Characteristics of patients diagnosed with cervical cancer in Brazil: preliminary results of the prospective cohort EVITA study (EVA001/LACOG 0215)

Angélica Nogueira Rodrigues, Andréia Cristina de Melo, Aknar Freire de Carvalho Calabrich, Eduardo Cronenberger, Kátia Luz Torres, Fernanda Damian, Rachel Cossetti, Carla Rameri Alexandre Silva de Azevedo, Alex Jardim da Fonseca, Yeni Nerón, João Nunes, André Lopes, Felipe Thomé, Renato Leal, Giuliano Borges, Arthur Ferreira da Silva, Matheus Führr Rodrigues, Paulo Ricardo Santos Nunes Filho, Facundo Zaffaroni, Raquel Dal Sasso Freitas, Gustavo Werutsky, Fernando Maluf

Master's and Doctoral Theses on LACOG Studies

GUSTAVO WERUTSKY | DOCTORAL THESIS

Socioeconomic impact on breast cancer patients in Brazil: sub-analysis of family entity of the AMAZONA III Study

PUCRS - Pontifícia Universidade Católica do Rio Grande do Sul
Porto Alegre, Brazil

ALESSANDRA BORBA ANTON DE SOUZA | MASTER THESIS

Access to genetic testing for hereditary breast cancer in a multicenter cohort study with 2,974 women with breast cancer

PUCRS - Pontifícia Universidade Católica do Rio Grande do Sul
Porto Alegre, Brazil

JÚLIO CÉSAR PRESTES | DOCTORAL THESIS

Assessment of sociodemographic aspects of patients diagnosed with breast cancer in relation to the time of initiation of radiotherapy

Hospital Sírio Libanês
São Paulo, Brazil

RAÍRA MESQUITA MASCHMANN | MASTER THESIS

Evaluation of the time elapsed from the diagnosis of breast cancer to the beginning of treatment in Brazilian patients: a sub-study of the project "AMAZONA III - Prospective evaluation of the Breast Cancer Casuistry in Brazilian Health Institutions"

UFCSA - Universidade Federal de Ciências da Saúde de Porto Alegre
Porto Alegre, Brazil

CARLA CASAGRANDE PAVEI | MASTER THESIS

Clinicopathologic and treatment characteristics of elderly patients with early-stage breast cancer in Brazil: A sub-analysis of AMAZONA III study (GBECAM 0115).

UFCSA - Universidade Federal de Ciências da Saúde de Porto Alegre
Porto Alegre, Brazil

FERNANDA DAMIAN | DOCTORAL THESIS

A phase 2 trial of palbociclib plus letrozole combination after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer (LACOG 1018)

UFCSA - Universidade Federal de Ciências da Saúde de Porto Alegre
Porto Alegre, Brazil

11 CONFERENCES AND EVENTS



The Brazilian Breast Cancer Conference 2022 – LACOG GBECAM and Best of SABCS® Brazil

The Brazilian Breast Cancer Conference 2022 - Best of SABCS Brazil was held at the Intercontinental Hotel in São Paulo between April 29 and 30. The event was organized by LACOG and the Brazilian Breast Cancer Study Group (GBECAM) in a hybrid format. Experts from all over Brazil and other countries gathered to discuss the main advances in the diagnosis and treatment of breast cancer.

During the two-day conference, participants were presented with key highlights of the San Antonio Breast Cancer Symposium, as well as modules devoted to the treatment of early and metastatic disease, significant advances in surgery, radiotherapy, and systemic treatments, and their implications for clinical practice.

The scientific program, presented by 36 national and international lecturers, was attended in-person and virtually by more than 1,117 individuals from various states.





Best of ASCO 2022

On June 10th and 11th, LACOG and Instituto Ética hosted the tenth edition of the Best of ASCO 2022 event at the Pullman Ibirapuera Hotel in São Paulo. The ASCO-licensed congress had nine modules delivered by renowned Brazilian oncologists. Approximately 1,126 individuals attended the event in-person and via live transmission.


During the event, 46 abstracts were presented between the modules Genitourinary, Skin Cancer, Sarcomas, Gastrointestinal, Hematology, Breast, Gynecology, Lung, Head and Neck and Neuro. Fernanda Schwyter, president of the CURA Project Institute, presented the Renata Thormann Procianny Award on this occasion. The winner of the fourth edition of the award was the researcher and nephrologist of the Cancer Institute of the State of São Paulo (ICESP), Dra. Verônica Torres, lead author of a study on aspects related to the management of renal treatment in cancer patients.



LATAM Cancer Connection: webinar series

From March 29th to March 31st, a series of webinars entitled LATAM Cancer Connection were held as part of a collaboration between LACOG and MSD. The series focused on breast, gynecological, and genitourinary modules and intended to bring technical knowledge to clinical practice in Latin America.

Renowned oncologists from several Latin American countries presented the latest developments in the following areas of the global scenario: triple-negative breast cancer, endometrial cancer: essential knowledge in 2022, and advances and challenges in genitourinary tumors. The program was conducted online, with Spanish, English, and Portuguese translations, and 1,310 medical oncologists from 15 countries registered.



LACOG Annual Scientific Meeting

On October 6th and 7th, the LACOG Annual Scientific Meeting was held in São Paulo. The event gathered in-person members of LACOG's 10 oncology specialty groups and included online participants from various Latin American countries. Among the discussions held during the meeting were ongoing studies from the groups, new proposals, and publications.

During Friday's program, the LACOG team presented the group's organizational structure and the new planned projects to all the attendees. It was a great honor to have so many members who support and work for the advancement of cancer research in Latin America present at this annual meeting.






LACOG Immuno-Oncology Symposium 2022

The first edition of the LACOG Immuno-Oncology Symposium was held on October 7th and 8th at the Sheraton São Paulo WTC hotel, with both in-person and online attendees. The event was the only one of its kind in Brazil and Latin America, focusing solely on immuno-oncology in clinical practice.

The speakers presented and discussed immunotherapy's fundamental principles and the most recent clinical research findings. The program was divided into modules titled Skin Tumors, Sarcoma and Lung, Breast, Gastrointestinal, Geriatric, Neuro, Gynecological, Genitourinary, and Head and Neck. The topics covered are intended to give oncologists an overview of each treatment area.



"Love for Research against Cancer" project meeting



The Instituto Vencer o Câncer was also present at the LACOG Immuno-Oncology Symposium 2022, where it held a meeting with pharmaceutical industry representatives to present the "Love for Research against Cancer" project research sites. This project, a collaboration between LACOG and the Instituto Vencer o Câncer, seeks to establish cancer control-critical research sites in regions of Brazil that currently lack them.

The event was attended by medical researchers representing the six sites selected for the project, namely Centro Integrado de Pesquisa da Amazônia (CINPAM) (AM), Hospital do Câncer do Maranhão Dr. Tarquínio Lopes Filho (MA), Hospital Napoleão Laureano (PB), Clínica Onconeo (MS), Hospital Santa Casa de Misericórdia de Feira de Santana (BA) and Hospital Universitário João de Barros Barreto da Universidade Federal do Pará (PA). During the program, there was also a discussion on how to promote clinical research in Brazil and reach those who need it the most.






VI GU Review International Symposium 2022 - IV Multiprofessional Symposium

The VI International GU Review Symposium and the IV Multiprofessional Symposium 2022 were held at the Intercontinental Hotel in São Paulo from November 17th to 19th, 2022. The events were hosted by LACOG Genitourinary Group in a hybrid format and presented updates on treatments for prostate, kidney, and bladder cancers, as well as recent studies on these neoplasms. In-person and virtual registrations totaled 1,617 for the three-day event, which featured 88 national lecturers and eight international speakers.

The IV Multiprofessional Symposium targeted oncology-focused nurses, pharmacists, physiotherapists, and nutritionists. The program covered topics such as safety in the process of antineoplastic infusion, effectiveness in the use of immunotherapies, among others.



London Global Cancer Week

On November 16th, LACOG, together with SLACOM, held the webinar "Experience of patient advocacy groups in support of cancer control and research in Latin America". The panel was part of the 2022 edition of London Global Cancer Week, a worldwide event that promotes discussions on cancer, its impact, and prevention in several countries.

The event featured speakers from Brazil, Argentina, and Mexico and included discussions on the significance of an early diagnosis for the patient's treatment, the need to raise funds and investments in clinical research, and the search for greater collaboration between institutions, patients, and society for cancer control.

12 LOVE FOR RESEARCH AGAINST CANCER PROJECT

The Instituto Vencer o Câncer (IVOC), in collaboration with LACOG, developed the project Amor à Pesquisa Contra o Câncer (Love for Research against Cancer) in Brazil, which was supported by the Associação da Indústria Farmacêutica de Pesquisa (Interfarma), Sindicato da Indústria de Produtos Farmacêuticos (Sindufarma), and Eurofarma. This initiative is a collaborative endeavor by researchers, health associations, and the private sector to expand oncology research in the country. The aim is to provide support for the establishment of new centers, particularly in regions where research is underdeveloped, such as the North and Northeast of Brazil, where there are fewer of these institutions. In addition to developing and organizing the operational structure and staff, and supplying technical and financial support, the project seeks to oversee the implementation of clinical studies and activities over a two-year period. The structuring and monitoring of the program's activities are directed by a management council comprised of Brazil's foremost clinical research specialists. The selection of centers was made through a public notice and was based on a number of factors, including the geographic location of the health institution, the institutional availability of a health professional to perform coordination activities, the evaluation of the institution's cancer population, the availability of physical space and equipment for clinical research, and the ability to perform the tests or the possibility of outsourcing them.



THE CENTERS SELECTED IN THE PUBLIC NOTICE WERE:

| |
|---|
| Centro Integrado de Pesquisa da Amazônia (Amazon Integrated Research Center), Manaus (AM) |
| Hospital Universitário João de Barros Barreto (João de Barros Barreto University Hospital), Belém (PA) |
| Hospital de Câncer Dr. Tarquínio Lopes Filho (Cancer Hospital Dr. Tarquínio Lopes Filho), São Luís (MA) |
| Hospital Napoleão Laureano (Napoleão Laureano Hospital) João Pessoa (PB) |
| Hospital Oncovida (Oncovida Hospital), Montes Claros (MG) |
| Clínica Onconeo Ltda. (Onconeo Clinic Ltda.), Campo Grande (MS) |

Some units have already started their clinical studies, including the center in São Luís, Maranhão, which will conduct research on kidney and prostate tumors; the unit in Campo Grande, Mato Grosso do Sul, which will conduct research on kidney and lung cancer; and the unit in Manaus, Amazonas, which will conduct research on HIV-related anal cancer and kidney tumors. The other centers are also already preparing to conduct studies in their units.

Before the start of the surveys, the centers received technical visits and inspections in the first half of 2022 as part of the process of implementing activities and training local teams.

"Clinical investigations are the scientific foundation for cancer diagnosis and treatment innovation and

development. Today, Brazil takes part in 5% of global cancer clinical trials and ranks fifteenth in terms of the number of clinical trials. As the president of LACOG, oncologist Gustavo Werutsky asserts, "We have enormous growth potential in conducting and participating in clinical studies in oncology for the benefit of patients, institutions, health professionals, and sponsors."

"This project aims to provide new research centers in regions where they have not yet been established in order for them to conduct international protocols. Oncologist Fernando Maluf, co-founder of the Instituto Vencer o Câncer institute, explains that patients from all regions of the country will now be able to be recruited for these studies.



Projeto cura.

Juntos,
pesquisando
a cura
do câncer.



The Cura Meetings Event

In 2022, the Instituto Projeto CURA held three editions of the Cura Meetings, an event centered on public policies, with the goal of increasing the knowledge and engagement of various sectors of society to reduce the incidence of cancer in Brazil and discussing research bottlenecks with the scientific community, medical and pharmaceutical researchers, and public agents and NGO leaders. The hybrid nature of the meetings provided the public with the opportunity to learn about the benefits and difficulties of conducting cancer research.



1st Cura Meetings

April 29, 2022 - Theme: "Clinical Research and Social Inclusion"



2nd Cura Meetings

June 10, 2022 - Theme: "The challenges of public policies aimed at regulating and encouraging oncology research in Brazil."



3rd Cura Meetings

October 7, 2022 - Theme: "Clinical research as a form of Social Inclusion - expanding access to clinical research in Brazil"

Renata Thormann Procianoy Award Ceremony 2022

The Renata Thormann Procianoy Award, conceived and administered by the Instituto Projeto Cura, aims to encourage the scientific community to continue its outstanding research and renew its motivation to aid others and future generations. Cura knows how challenging and stressful research in Brazil can be due to the lack of incentives. This is its contribution to the recognition of Brazilian cancer researchers and their effort.

On June 10th, 2022, the Instituto Projeto Cura presented the 3rd Renata Thormann Procianoy Award, during the Best of Asco, to Dr. Verônica, who is the first author of the article titled "Prospective study evaluates the performance of the 2021 CKD-EPI equation without race coefficient in adults with solid tumors" regarding renal treatment for cancer patients.



Research Saves Lives Movement

On October 11th, 2022, the Instituto Projeto Cura launched the institutional campaign Movimento Pesquisas Salvam Vidas (Research Saves Lives Movement), an initiative that will serve as an additional informational front regarding the benefits of clinical research and its nuances from the perspective of the primary beneficiary: the patient. The Movement had the institutional support of NGOs.

It is through clinical research that medical advancements are made. Research is necessary so that we can learn more about diseases and develop new medicines, vaccines, and exams. The cure for cancer is also based on research. This, however, requires overcoming numerous obstacles, such as funding, promoting awareness, regulation, and encouraging scientific production. In view of these challenges, the Instituto Projeto Cura idealized the movement research saves lives **#PesquisasSalvamVidas**.




1st Immunotherapy Forum for patients

On October 8th, 2022, the Instituto Projeto Cura hosted the 1st Immunotherapy Forum for Patients with the theme "Access to Immunotherapy in Brazil through Clinical Research." This was an occasion for lay patients and NGO leaders to clarify their questions with experts in the field and learn more about the topic, thereby expanding their knowledge. The Forum was held in a hybrid format, allowing more individuals to access the information presented.

London Global Cancer Week 2022

On November 16th, the Instituto Projeto Cura participated in the London Global Cancer Week webinar that presented the actions to support cancer research conducted by Latin American cancer patient associations. The program was conducted by LACOG and SLACOM and featured speakers from renowned institutions in Brazil, Argentina, and Mexico.



Survey

The Instituto Projeto CURA conducted a scientific study entitled "A national survey of the current situation and future prospects of cancer research in Brazil." The survey was created in collaboration with LACOG to assess the current behavior and prospective trends of Brazilian oncologists regarding clinical research in the treatment of cancer patients.

This scientific study, conceived and executed in 2022, has been submitted and accepted for publication at ASCO 2023, the world's largest oncology conference. It is worth pointing out some relevant data from the survey:

- Most of the participating physicians work in capital cities and are exclusively affiliated with private services.
- Two-thirds of participating physicians discuss clinical research with fewer than five percent of their patients.

These and other data generated by this survey will be crucial for guiding new public policies and strategies to expand access to scientific research and improve patient treatment.

The authors of the study were: Heloisa Resende, Taiane Rebelatto, Gustavo Werutsky, Gustavo Gössling, Vinicius Aguiar, Guilherme Lopes, Biazzi Assis, Lilian Martins Arruda and Carlos H. Barrios.



@lacog.org.br



/lacog



/lacog.org



/bit.do/lacog



@lacogg